» Authors » Bianka Wissuwa

Bianka Wissuwa

Explore the profile of Bianka Wissuwa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 261
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller T, Krieg N, Lange-Polovinkin A, Wissuwa B, Graler M, Dennhardt S, et al.
Int J Mol Sci . 2024 Jul; 25(14). PMID: 39062926
Typical hemolytic uremic syndrome (HUS) can occur as a severe systemic complication of infections with Shiga toxin (Stx)-producing . Its pathology can be induced by Stx types, resulting in toxin-mediated...
2.
Neu C, Wissuwa B, Thiemermann C, Coldewey S
Front Immunol . 2023 Oct; 14:1252818. PMID: 37809105
Introduction: Hemolytic-uremic syndrome (HUS) can occur as a systemic complication of infection with Shiga toxin (Stx)-producing Escherichia coli (STEC). Most well-known aspects of the pathophysiology are secondary to microthrombotic kidney...
3.
Kroller S, Wissuwa B, Dennhardt S, Krieg N, Thiemermann C, Daniel C, et al.
Front Immunol . 2023 Mar; 14:1105181. PMID: 36911665
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-producing . Patients typically present with acute kidney injury, microangiopathic hemolytic anemia and thrombocytopenia. There is evidence...
4.
Dennhardt S, Pirschel W, Wissuwa B, Imhof D, Daniel C, Kielstein J, et al.
Front Immunol . 2022 Oct; 13:1010882. PMID: 36211426
Hemolytic-uremic syndrome (HUS) can occur as a systemic complication of infections with Shiga toxin (Stx)-producing and is characterized by microangiopathic hemolytic anemia and acute kidney injury. Hitherto, therapy has been...
5.
Herminghaus A, Kozlov A, Szabo A, Hantos Z, Gylstorff S, Kuebart A, et al.
Front Immunol . 2022 Jul; 13:895100. PMID: 35874776
Pulmonary diseases represent four out of ten most common causes for worldwide mortality. Thus, pulmonary infections with subsequent inflammatory responses represent a major public health concern. The pulmonary barrier is...
6.
Pirschel W, Mestekemper A, Wissuwa B, Krieg N, Kroller S, Daniel C, et al.
Kidney Int . 2022 Jan; 101(6):1171-1185. PMID: 35031328
Thrombotic microangiopathy, hemolysis and acute kidney injury are typical clinical characteristics of hemolytic-uremic syndrome (HUS), which is predominantly caused by Shiga-toxin-producing Escherichia coli. Free heme aggravates organ damage in life-threatening...
7.
Mohammad S, Al Zoubi S, Collotta D, Krieg N, Wissuwa B, Alves G, et al.
Front Immunol . 2021 Aug; 12:701275. PMID: 34349763
Metabolic endotoxemia has been suggested to play a role in the pathophysiology of metaflammation, insulin-resistance and ultimately type-2 diabetes mellitus (T2DM). The role of endogenous antimicrobial peptides (AMPs), such as...
8.
ORiordan C, Purvis G, Collotta D, Krieg N, Wissuwa B, Sheikh M, et al.
Front Immunol . 2020 Nov; 11:581758. PMID: 33162995
We previously reported the Bruton's tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib improve outcomes in a mouse model of polymicrobial sepsis. Now we show that genetic deficiency of the BTK...
9.
Zechendorf E, ORiordan C, Stiehler L, Wischmeyer N, Chiazza F, Collotta D, et al.
JCI Insight . 2020 Mar; 5(8). PMID: 32213712
Septic cardiomyopathy is a life-threatening organ dysfunction caused by sepsis. Ribonuclease 1 (RNase 1) belongs to a group of host-defense peptides that specifically cleave extracellular RNA (eRNA). The activity of...
10.
ORiordan C, Purvis G, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S, et al.
Front Immunol . 2019 Sep; 10:2129. PMID: 31552054
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine...